tiprankstipranks
Advertisement
Advertisement

BIIB Stock Latest News

Biogen Earnings Call Signals Confident, Investment-Heavy Transition
Company AnnouncementsBiogen Earnings Call Signals Confident, Investment-Heavy Transition
2d ago
BIIB
Immunic appoints Michael Bonney as chair
PremiumThe Fly
Immunic appoints Michael Bonney as chair
2d ago
BIIB
IMUX
Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250
PremiumRatings
Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250
6d ago
BIIB
Biogen: Hold Rating Reiterated as Pipeline Concerns Offset Leqembi Growth; $196 Price Target Maintained
PremiumRatings
Biogen: Hold Rating Reiterated as Pipeline Concerns Offset Leqembi Growth; $196 Price Target Maintained
6d ago
BIIB
Cisco upgraded, Doximity downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Cisco upgraded, Doximity downgraded: Wall Street’s top analyst calls
6d ago
AOS
PHR
Biogen resumed with an Outperform at Evercore ISI
PremiumThe FlyBiogen resumed with an Outperform at Evercore ISI
6d ago
BIIB
Biogen price target raised to $225 from $214 at Piper Sandler
Premium
The Fly
Biogen price target raised to $225 from $214 at Piper Sandler
6d ago
BIIB
Hold Rating Maintained on Biogen as BIIB080 Moves to Phase 3; Risk-Reward Seen Balanced with Unchanged $206 Price Target
Premium
Ratings
Hold Rating Maintained on Biogen as BIIB080 Moves to Phase 3; Risk-Reward Seen Balanced with Unchanged $206 Price Target
6d ago
BIIB
Biogen Buy Rating Reiterated as Tau Data Eases Overhang; Price Target Maintained at $225
PremiumRatings
Biogen Buy Rating Reiterated as Tau Data Eases Overhang; Price Target Maintained at $225
6d ago
BIIB
Biogen Rated Hold as Analyst Cites Mixed Alzheimer’s Data and Commercial Hurdles; $203 Price Target Reiterated
PremiumRatings
Biogen Rated Hold as Analyst Cites Mixed Alzheimer’s Data and Commercial Hurdles; $203 Price Target Reiterated
6d ago
BIIB
Biogen CELIA topline readout in Alzheimer’s ‘historic,’ says H.C. Wainwright
PremiumThe Fly
Biogen CELIA topline readout in Alzheimer’s ‘historic,’ says H.C. Wainwright
7d ago
DYN
ALEC
Biogen Buy Rating Reiterated as CELIA Phase 2 Diranersen Data De-Risk Tau Strategy and Support Unchanged $237 Price Target
PremiumRatings
Biogen Buy Rating Reiterated as CELIA Phase 2 Diranersen Data De-Risk Tau Strategy and Support Unchanged $237 Price Target
7d ago
BIIB
Biogen’s SKYCLARYS Formulation Study: What a New Liquid Tablet Could Mean for BIIB Investors
PremiumCompany AnnouncementsBiogen’s SKYCLARYS Formulation Study: What a New Liquid Tablet Could Mean for BIIB Investors
7d ago
BIIB
Minter Reiterates Buy on Biogen as Tau-Targeting Diranersen Data Signals Clinically Meaningful Cognitive Benefit and Strong Biomarker Validation
Premium
Ratings
Minter Reiterates Buy on Biogen as Tau-Targeting Diranersen Data Signals Clinically Meaningful Cognitive Benefit and Strong Biomarker Validation
7d ago
BIIB
Video: Cisco surges as AI powers better-than-anticipated forecast
Premium
The Fly
Video: Cisco surges as AI powers better-than-anticipated forecast
7d ago
VIK
BIIB
Biogen completes acquisition of Apellis Pharmaceuticals
PremiumThe Fly
Biogen completes acquisition of Apellis Pharmaceuticals
7d ago
APLS
BIIB
Morning Movers: Klarna and Yeti rise following quarterly earnings
PremiumThe Fly
Morning Movers: Klarna and Yeti rise following quarterly earnings
7d ago
VIK
BIIB
Biogen’s diranersen shows benefits in early Alzheimer’s Disease
PremiumThe Fly
Biogen’s diranersen shows benefits in early Alzheimer’s Disease
7d ago
BIIB
IONS
Ionis announces Biogen’s CELIA study did not meet primary endpoint
PremiumThe Fly
Ionis announces Biogen’s CELIA study did not meet primary endpoint
7d ago
BIIB
IONS
Biogen Completes Apellis Acquisition to Strengthen Growth
PremiumCompany AnnouncementsBiogen Completes Apellis Acquisition to Strengthen Growth
7d ago
8K
BIIB
Biogen up 8% at $220 after Phase 2 diranersen data in Alzheimer’s Disease
Premium
The Fly
Biogen up 8% at $220 after Phase 2 diranersen data in Alzheimer’s Disease
7d ago
BIIB
Biogen: FDA Delay on Subcutaneous Lecanemab Seen as Timing Issue; Hold Rating Reiterated with Unchanged $203 Price Target
Premium
Ratings
Biogen: FDA Delay on Subcutaneous Lecanemab Seen as Timing Issue; Hold Rating Reiterated with Unchanged $203 Price Target
11d ago
BIIB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >